Defusing US Opioid Crisis Offers Orexo "Strong Growth Potential" Says CEO

10 Apr 2019

• By Sten Stovall

The CEO of Swedish addiction and pain specialist Orexo tells Scrip its top drug Zubsolv will grow strongly in coming years to address the opioid crisis in the US, and that revenues will be further boosted by novel pipeline therapies likely to be commercialized in coming years.

USA_Stethoscope — Orexo believes US will increasingly turn to its novel opioid dependence therapies • Source: Shutterstock

Orexo AB’s leading product Zubsolv, for opioid dependence, will enjoy strong sales in the US as the healthcare system copes with the growing crisis of addiction there, giving the Swedish specialty pharma the solid platform to expand its pipeline while pursuing M&A possibilities, its CEO predicted in an interview with Scrip.

The Swedish-listed speciality pharma was founded 1995 to use its drug delivery technologies to develop and market products to treat...